Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.
Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
Sublocade (buprenorphine) and Suboxone (buprenorphine/naloxone) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat opioid use disorder (OUD).
Monthly injections work great. Patients come in once a month, get their shot, and can focus on the rest of their treatment.” — Samantha Callister, Executive Director Integrity Treatment Partners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results